Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis
Background. Observational studies have shown percutaneous patent foramen ovale (PFO) closure to be a safe means of reducing the frequency and duration of migraine. Objective. This study evaluated the efficacy and safety of PFO closure in patients with migraine using evidence-based medicine. Methods....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2022/6456272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548422783074304 |
|---|---|
| author | Yu Zhang Haijiao Wang Ling Liu |
| author_facet | Yu Zhang Haijiao Wang Ling Liu |
| author_sort | Yu Zhang |
| collection | DOAJ |
| description | Background. Observational studies have shown percutaneous patent foramen ovale (PFO) closure to be a safe means of reducing the frequency and duration of migraine. Objective. This study evaluated the efficacy and safety of PFO closure in patients with migraine using evidence-based medicine. Methods. The Pubmed (MEDLINE), Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs), cohort studies, and retrospective case series from January 1, 2001, to February 30, 2021. The Jadad scale and R 4.1.0 software were used to assess the quality of the literature and meta-analysis, respectively. Results. In total, three randomized controlled trials, one pooled study, and eight retrospective case series including 1,165 participants were included in the meta-analysis. Compared with control intervention in migraine, PFO closure could significantly reduce headache frequency (OR = 1.5698, 95% CI: 1.0465–2.3548, p=0.0293) and monthly migraine attacks and monthly migraine days (OR = 0.2594, 95% CI: 0.0790–0.4398, p=0.0048). Subgroup analysis of patients who all completed PFO surgery showed resolution of migraine headache for migraines with aura (OR = 1.5856, 95% CI: 1.0665–2.3575, p=0.0227). Conclusions. Treatment with PFO closure could reduce the frequency of headaches and monthly migraine days and is an efficient treatment for migraine attacks with aura. |
| format | Article |
| id | doaj-art-b55fd22dffdf401089d087e7fec7b996 |
| institution | Kabale University |
| issn | 1540-8183 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-b55fd22dffdf401089d087e7fec7b9962025-02-03T06:14:11ZengWileyJournal of Interventional Cardiology1540-81832022-01-01202210.1155/2022/6456272Patent Foramen Ovale Closure for Treating Migraine: A Meta-AnalysisYu Zhang0Haijiao Wang1Ling Liu2Department of NeurologyDepartment of NeurologyDepartment of NeurologyBackground. Observational studies have shown percutaneous patent foramen ovale (PFO) closure to be a safe means of reducing the frequency and duration of migraine. Objective. This study evaluated the efficacy and safety of PFO closure in patients with migraine using evidence-based medicine. Methods. The Pubmed (MEDLINE), Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs), cohort studies, and retrospective case series from January 1, 2001, to February 30, 2021. The Jadad scale and R 4.1.0 software were used to assess the quality of the literature and meta-analysis, respectively. Results. In total, three randomized controlled trials, one pooled study, and eight retrospective case series including 1,165 participants were included in the meta-analysis. Compared with control intervention in migraine, PFO closure could significantly reduce headache frequency (OR = 1.5698, 95% CI: 1.0465–2.3548, p=0.0293) and monthly migraine attacks and monthly migraine days (OR = 0.2594, 95% CI: 0.0790–0.4398, p=0.0048). Subgroup analysis of patients who all completed PFO surgery showed resolution of migraine headache for migraines with aura (OR = 1.5856, 95% CI: 1.0665–2.3575, p=0.0227). Conclusions. Treatment with PFO closure could reduce the frequency of headaches and monthly migraine days and is an efficient treatment for migraine attacks with aura.http://dx.doi.org/10.1155/2022/6456272 |
| spellingShingle | Yu Zhang Haijiao Wang Ling Liu Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis Journal of Interventional Cardiology |
| title | Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis |
| title_full | Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis |
| title_fullStr | Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis |
| title_full_unstemmed | Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis |
| title_short | Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis |
| title_sort | patent foramen ovale closure for treating migraine a meta analysis |
| url | http://dx.doi.org/10.1155/2022/6456272 |
| work_keys_str_mv | AT yuzhang patentforamenovaleclosurefortreatingmigraineametaanalysis AT haijiaowang patentforamenovaleclosurefortreatingmigraineametaanalysis AT lingliu patentforamenovaleclosurefortreatingmigraineametaanalysis |